Skip to main content
. 2017 Mar 21;8(22):35946–35961. doi: 10.18632/oncotarget.16412

Figure 2. Reparixin inhibits TC cell proliferation by decreasing DNA synthesis and cell survival.

Figure 2

(A) BrdU incorporation at 24 h of 8505c, CAL62 and SW1736 treated with Reparixin (30 μM) both in the absence and presence of exogenous IL-8 (100 ng/ml). *p < 0.05 compared to untreated cells (NT); §p < 0.05 compared to IL-8 treated cells. (B) Percent of apoptotic cells assessed by TUNEL reaction in 8505c, CAL62 and SW1736 treated with Reparixin (30 μM) both in the absence and presence for 24 h of exogenous IL-8 (100 ng/ml). *p < 0.05 compared to untreated cells (NT); §p < 0.05 compared to IL-8 treated cells. (C) Cell cycle distribution of 8505c, CAL62 and SW1736 cells treated with Reparixin (30 μM), in the absence or in the presence of exogenous IL-8 (100 ng/ml), measured by Propidium Iodide (PI) staining by means of Flow Cytometry at 24 h. The percent of the cells distributed in G1, S, G2/M was indicated in each panel. A representative graph of SW1736 cell cycle was shown.